Smith & Nephew Dividends - SN.

Best deals to access real time data!
Level 2 Basic Monthly Subscription for only ~~£62.08~~
Silver Monthly Subscription for only ~~£17.37~~
UK/US Silver Monthly Subscription for only £30.59
VAT not included

Stock Name	Stock Symbol	Market	Stock Type	Stock ISIN	Stock Description
Smith & Nephew Plc	SN.	London	Ordinary Share	GB0009223206	ORD USD0.20

	Price Change	Price Change %	Stock Price	Low Price	High Price	Open Price	Close Price	Last Trade
	-5.50	-0.39%	1,422.00	1,381.00	1,455.00	1,399.50	1,427.50	15:12:59

more quote information »

Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Smith & Nephew SN. Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
20/02/2020	Final	USX	23.1	31/12/2018	31/12/2019	02/04/2020	03/04/2020	06/05/2020	37.5
31/07/2019	Interim	USX	14.4	31/12/2018	31/12/2019	03/10/2019	04/10/2019	30/10/2019	0
07/02/2019	Final	USX	22	31/12/2017	31/12/2018	04/04/2019	05/04/2019	08/05/2019	36
26/07/2018	Interim	USX	14	31/12/2017	31/12/2018	04/10/2018	05/10/2018	31/10/2018	0
08/02/2018	Final	USX	22.7	31/12/2016	31/12/2017	05/04/2018	06/04/2018	09/05/2018	35
27/07/2017	Interim	USX	12.3	31/12/2016	31/12/2017	05/10/2017	06/10/2017	01/11/2017	0
09/02/2017	Final	USX	18.5	31/12/2015	31/12/2016	30/03/2017	31/03/2017	10/05/2017	30.8
28/07/2016	Interim	USX	12.3	31/12/2015	31/12/2016	06/10/2016	07/10/2016	25/10/2016	0
04/02/2016	Final	USX	19	31/12/2014	31/12/2015	21/04/2016	22/04/2016	11/05/2016	30.8
30/07/2015	Interim	USX	11.8	31/12/2014	31/12/2015	08/10/2015	09/10/2015	27/10/2015	0
05/02/2015	Final	USX	18.6	31/12/2013	31/12/2014	16/04/2015	17/04/2015	06/05/2015	29.6
01/08/2014	Interim	USX	11	31/12/2013	31/12/2014	22/10/2014	24/10/2014	11/11/2014	0
06/02/2014	Final	USX	17	31/12/2012	31/12/2013	20/04/2014	22/04/2014	07/05/2014	27.4
01/08/2013	Interim	USX	10.4	31/12/2012	31/12/2013	09/10/2013	11/10/2013	29/10/2013	0
07/02/2013	Final	USX	16.2	31/12/2011	31/12/2012	17/04/2013	19/04/2013	08/05/2013	26.1
02/08/2012	Interim	USX	9.9	31/12/2011	31/12/2012	10/10/2012	12/10/2012	30/10/2012	0
02/02/2012	Final	USX	10.8	31/12/2010	31/12/2011	18/04/2012	20/04/2012	09/05/2012	17.4
05/08/2011	Interim	USX	6.6	31/12/2010	31/12/2011	12/10/2011	14/10/2011	01/11/2011	0
10/02/2011	Final	USX	9.82	31/12/2009	31/12/2010	01/05/2011	03/05/2011	19/05/2011	15.82
05/08/2010	Interim	USX	6	31/12/2009	31/12/2010	13/10/2010	15/10/2010	02/11/2010	0
12/02/2010	Final	USX	8.93	31/12/2008	31/12/2009	21/04/2010	23/04/2010	12/05/2010	14.39
30/07/2009	Interim	USX	5.46	30/12/2008	30/06/2009	14/10/2009	16/10/2009	03/11/2009	0
12/02/2009	Final	USX	8.12	31/12/2007	31/12/2008	15/04/2009	17/04/2009	08/05/2009	13.58
07/08/2008	Interim	USX	4.96	28/12/2007	28/06/2008	15/10/2008	17/10/2008	07/11/2008	0
07/02/2008	Final	USX	7.38	31/12/2006	31/12/2007	16/04/2008	18/04/2008	09/05/2008	11.89
02/08/2007	Interim	USX	4.51	30/12/2006	30/06/2007	17/10/2007	19/10/2007	09/11/2007	0
08/02/2007	Interim	USX	3.41	31/12/2005	31/12/2006	18/04/2007	20/04/2007	11/05/2007	0
08/02/2007	Final	USX	0	31/12/2005	31/12/2006	01/01/1970	01/01/1970	01/01/1970	5.62
27/07/2006	Interim	USX	2.21	01/01/2006	01/07/2006	18/10/2006	20/10/2006	10/11/2006	0
09/02/2006	Final	USX	3.5	31/12/2004	31/12/2005	19/04/2006	21/04/2006	12/05/2006	5.6
04/08/2005	Interim	USX	2.1	30/12/2004	30/06/2005	19/10/2005	21/10/2005	11/11/2005	0
03/02/2005	Final	USX	3.2	31/12/2003	31/12/2004	20/04/2005	22/04/2005	13/05/2005	5.1
05/08/2004	Interim	USX	1.9	03/01/2004	03/07/2004	20/10/2004	22/10/2004	12/11/2004	0
05/02/2004	Final	USX	3.1	31/12/2002	31/12/2003	21/04/2004	23/04/2004	14/05/2004	4.95
31/07/2003	Interim	USX	1.85	28/12/2002	28/06/2003	13/08/2003	15/08/2003	12/09/2003	0
07/02/2003	Final	USX	3	31/12/2001	31/12/2002	20/04/2003	22/04/2003	16/05/2003	4.8
01/08/2002	Interim	USX	1.8	30/12/2001	30/06/2002	16/10/2002	18/10/2002	15/11/2002	0
07/02/2002	Final	USX	2.9	31/12/2000	31/12/2001	17/04/2002	19/04/2002	17/05/2002	4.65
02/08/2001	Interim	USX	1.75	30/12/2000	30/06/2001	07/11/2001	09/11/2001	05/12/2001	0
15/02/2001	Final	USX	2.8	31/12/1999	31/12/2000	18/04/2001	20/04/2001	18/05/2001	4.5
05/07/2000	Special	USX	37.14	31/12/1999	31/12/2000	07/08/2000	04/08/2000	11/08/2000	0
08/08/2000	Interim	USX	1.7	01/01/2000	01/07/2000	06/11/2000	10/11/2000	06/12/2000	0
23/02/2000	Final	USX	4	31/12/1998	31/12/1999	02/05/2000	08/05/2000	02/06/2000	6.5
09/08/1999	Interim	USX	2.5	03/01/1999	03/07/1999	01/11/1999	05/11/1999	08/12/1999	0
25/02/1999	Final	USX	3.8	31/12/1997	31/12/1998	04/05/1999	10/05/1999	04/06/1999	6.2
26/02/1998	Final	USX	3.8	31/12/1996	31/12/1997	01/06/1998	05/06/1998	01/07/1998	6.2

Top Dividend Posts

Date	Subject
21/10/2019 21:50	kknight01: The company is certainly strong and I think what Namal brought was some guts to go out and start buying up small med tech companies to bolster the portfolio which if definitely the right way to go. I do hope his successor continues the momentum, sales are not going to diminish due to his departure, I think it is safe to day that medical device manufacturers are a good buy, with people living longer and the demand on healthcare increasing. The majority of the share price valuation was based on Namal's attitude to business and believe it will recover in time. In my opinion, we have an excellent t buying opportunity ahead and like you said, could very well be snapped up by a bigger fish any time. Read Full Thread Follow Reply
21/10/2019 09:55	steeplejack: Smith & Nephew"Can anything stop the exodus of FTSE 100 chief executives in 2019? The numbers have now been bolstered to the point where these departing CEOs could almost cobble together an 11-a-side football match as Smith & Nephew's Namal Nawana steps down."Australian Nawana has only been in post for 18 months but has already helped revive the share price with a new strategy."This culminated in re-organising the business into three global franchises: orthopaedics, sports medicine and advanced wound management."The market responded positively to this simplified structure, which reduced duplication of effort and made reporting responsibilities clearer with better accountability."There appears to be a pretty simple reason Nawana is leaving pay. It became apparent over the summer that the company was looking for ways to increase its head honcho's remuneration with apparent discussions about a move to a US listing to escape an increasing backlash in the UK towards excessive executive pay."The fear will be that this revamp of the business will be derailed by Nawana's departure despite efforts to allay these concerns with internal candidate Roland Diggelmann stepping up to the top job and Nawana staying to smooth the transition until the end of the year."Diggelmann faces a tricky task of balancing the need for continuity with a likely ambition to bring his own ideas to the role." Read Full Thread Follow Reply
19/8/2019 21:08	adamb1978: How much of the share price performance is simply FX driven? They report in $ and I suspect price in $ meaning having the £ head to the low 1.20s vs the $ helps them materially - its all extra revenue with no cost against it so falls straight through to the bottom line Read Full Thread Follow Reply
11/2/2019 12:20	steeplejack: Smith & Nephew was the biggest faller on the FTSE 100 this morning with shares down more than four per cent on reports it is in talks to buy US spine technology Nuvasive in a $3bn (£2.32bn) deal. Shares fell 4.39 per cent to 1,448p today, having closed on Friday at 1,515p. The Financial Times reported the potential deal on Friday after markets closed, sending Nuvasive’s share price up 25 per cent in after hours trading. Read Full Thread Follow Reply
08/2/2019 04:45	kknight01: I would say hold and watch this space. Olivier was a waste of space. Namal has brought in a strong leadership with particular emphasis on commercial and operations. Exciting times ahead for this great British company and if it does go wrong I would expect take over bid rumours for some on its franchises which will only push up the share price some more. Buy back when share price dips again! Read Full Thread Follow Reply
03/5/2018 08:17	steeplejack: The guidance has been trimmed from revenue growth of 3-4% at the time of the finals to 2-3% now.The suggestion is that things will stabilise and return to a more normal pattern in the rest of the year.Emerging markets are encouraging.Whether this update is worth over 7% off the share price is questionable especially given the corporate activity just now in the sector.Yet the shares have been very strong of late and are vulnerable to top slicing.Maybe I'm too simplistic but I never really worry about my holding in Smith & Nephew.I always feel that if things take an enduring turn for the worse,someone will take the company over. Read Full Thread Follow Reply
19/1/2018 08:39	basil brush1: imo lots of support at 1230. the big question is will there be a bid before the new CEO is appointed? looks vulnerable as share price has not changed in dollar terms in nearly 4 years. Stryker has doubled in the same period. Read Full Thread Follow Reply
26/11/2016 09:06	accipitridae: Get hip to Smith & Nephew's investment appeal, Goldman advises Share 10:36 25 Nov 2016 The hip and joint replacement specialist trades at a discount to sector peer Stryker Goldman Sachs has lowered its earnings estimates for Smith & Nephew PLC (LON:SN. but still rates the medical technology company’s shares a ‘buy’. The estimate changes follow the third quarter trading update earlier this morning and recent exchange rate movements, and see this year’s earnings per share (EPS) forecast decline 3%, while EPS estimates for the next three years have been shaved by 8%, reflecting weaker growth patterns in the third quarter. “While organic revenue growth this year has fallen short of our expectations (we now expect Smith & Nephew to deliver 1.9% organic revenue growth in 2016, down from the 5% that we had forecast at the beginning of 2016, with the slowdown driven largely by China and the Middle East), we continue to believe that SN.L will accelerate organic revenue growth into the 4%-5% range in 2017 and beyond, given its geographic and product mix (>50% of revenues is in higher-growth markets) and a number of upcoming product launches (Renasys Touch and Connect, Navio in total knee, revision hip, and WereWolf),” the heavyweight US investment bank said. The next catalyst for the share price is likely to be the appointment of a chief financial officer, expected before the end of the year. Goldman’s lowered its price target to 1,310p from 1,370p, on the assumption that Smith & Nephew will trade around 18 times projected EPS for 2018; it currently trades at 15.4 times 2018 EPS, whereas sector peer Stryker Corporation (NYSE:SYK) trades on an earnings multiple of 17.4, despite a comparable growth outlook. Goldman deems the disparity as unwarranted, and in fact suggests S&N should trade at a premium to Stryker, thanks to the possibility of being taken out by a competitor. Read Full Thread Follow Reply
10/8/2016 12:12	mikeindevon: Whichever way you look at it that 300m, 25p per share is 'lost' to the company ... it's not being used to grow the business, it's not being used to invest in new plant or projects it's being spent in an incestuous deal to buy back its own shares. Apart from a small, temporary fillip to the share price ... and yesterdays buy of £4m worth of shares produced zero addition of value ... it does nothing for us small shareholders. Rather it deprives us of 2% of yield. But it does increase the EPS by about the same amount ... by cancelling shares. So who does that benefit? It only benefits folk who hold few or no shares but gain from an increase in EPS ... and that smacks of bonus related management payments to me. As I say, call me a cynic ... but that's why I say buy backs are bad news to shareholders ... of course if I was particularly jaundiced I'd be thinking that maybe the brokers have a specific buyer that they buy the shares from ... but that would be a very different game and completely contrary to the free and open market principle. Mike Read Full Thread Follow Reply
01/4/2014 22:15	knighty0001: President of AWM Roger Teasdale is leaving the business at the end of the month. Has this been announced externally yet? Not sure what impact to share price this could have? If any at all. Read Full Thread Follow Reply

Advertise Here

Your Recent History

LSE

SN.

Smith & Ne..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20200330 14:28:02